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ABSTRACT Efficient methods for cell line transfection are
well described, but, for primary neurons, a high-yield method
different from those relying on viral vectors is lacking. Viral
transfection has several drawbacks, such as the complexity of
vector preparation, safety concerns, and the generation of
immune and inflammatory responses when used in vivo.
However, one of the main problems for the use of non-viral
gene vectors for neuronal transfection is their low efficiency
when compared with viral vectors. Transgene expression, or
siRNA delivery mediated by non-viral vectors, is the result of
multiple processes related to cellular membrane crossing,
intracellular traffic, and/or nuclear delivery of the genetic
material cargo. This review will deal with the barriers that
different nanoparticles (cationic lipids, polyethyleneimine, den-
drimers and carbon nanotubes) must overcome to efficiently
deliver their cargo to central nervous system cells, including
internalization into the neurons, interaction with intracellular
organelles such as lysosomes, and transport across the nuclear
membrane of the neuron in the case of DNA transfection.
Furthermore, when used in vivo, the nanoparticles should
efficiently cross the blood-brain barrier to reach the target cells
in the brain.
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INTRODUCTION
Gene therapy can be defined, in a broad sense, as an
attempt to introduce effective genes into malfunctioning
target cells from patients suffering from diseases of genetic
origin or to interfere with signaling pathways involved in
the genesis of different diseases by selectively knocking
down different proteins using RNA interference technology.
This approach has been shown to be especially useful in
tumoral cell lines (1). Neurons, however, are difficult to
transfect, and initial strategies to deliver genetic material to
neurons have relied on the use of viral vectors. This
approach has several drawbacks, especially safety concerns
and the possibility of an immune response against the viral
agents employed.
The use of non-viral vectors has been proposed to
overcome the aforementioned drawbacks of their viral
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counterparts. However, one of the main problems of such
non-viral gene vectors is their low transfection efficiency
compared with viral vectors (2, 3). Transgene expression, or
siRNA delivery mediated by non-viral vectors, is the result
of multiple processes related to cellular membrane crossing,
intracellular traffic and/or nuclear delivery of the genetic
material cargo.
This review will deal with the barriers that different
nanoparticles (NPs) (cationic lipids, polyethyleneimine, den-
drimers and carbon nanotubes) must overcome to efficiently
deliver their cargo to central nervous system (CNS) cells,
including a) internalization into the neurons, b) interaction
with intracellular organelles such as lysosomes, and c)
transport across the nuclear membrane of the neuron in
the case of DNA transfection. Furthermore, when used in
vivo, the nanoparticles should efficiently cross the blood-
brain barrier (BBB) to reach the target cells in the brain.
BARRIERS TO CELLULAR UPTAKE
Neuronal cells have special properties, such as their
polarized nature and the elongated morphology of neuro-
nal projections, which could result in barriers to uptake that
are unique to such cells (4). Fortunately, however, the
surface of nanomaterials can be designed to obtain specific
physical or biological properties, thereby allowing specific
interactions with cytoplasmic membranes and improving
this uptake. The internalization pathway includes two
subtypes, namely phagocytosis and pinocytosis (Fig. 1).
Non-viral vectors can take advantage of multiple uptake
pathways simultaneously in order to become internalized in
cells, although some of these lead to degradation when uptake
is higher than the efficiency of the treatment. However, this
diversity of uptake pathways makes the use of NPs to deliver
therapeutic molecules into neuronal cells possible (4).
Phagocytosis
Nanoparticle uptake mechanisms are different for neurons
and glia. Thus, in macrophage-like cells, such as microglia,
the internalization of nanocarriers up to 10 μm in diameter
depends heavily on phagocytic activity, a process that does
not take place in neuronal cells (5). Phagocytosis plays an
important physiological role in the clearance of apoptotic
cells by preventing the efflux of potentially harmful
components from dying cells, thereby limiting direct tissue
injury, and by inhibiting secondary immune responses (6).
In addition, microglial phagocytosis represents a first line of
defense against pathogens in the CNS.
The composition of NPs plays a critical role in phagocy-
tosis, and functionality at the surface of the nanocarriers seem
to be the most important driving force for phagocytosis,
although other characteristics of the NPs, such as their rigidity
and shape, may also have an effect on phagocytosis (7).
When NPs are used as non-viral delivery systems, the
main role of the cells involved in phagocytosis in the CNS is
to clear NPs from the brain. This internalization pathway
therefore plays a critical physiological role by reducing the
toxicity and effectiveness of most NPs used for drug or
genetic material delivery. Additionally, degradation by
macrophages also results in degradation of these nano-
carriers before they reach the CNS (8).
Pinocytosis
Non-phagocytic endocytosis, traditionally referred to as
pinocytosis, forms part of the whole cell membrane flux
Fig. 1 Scheme representing the
different mechanisms of nanopar-
ticle ( ) internalization, including
(a) macropinocytosis, (b) clathrin-
mediated endocytosis, (c)
caveolae-mediated endocytosis,
(d) clathrin and caveolae-
independent endocytosis and (e)
transduction. Dashed lines repre-
sent alternative pathways.
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that facilitates communication between the cell and the
extracellular environment. This process allows cells to
internalise molecules from the external environment for
metabolic purposes, recycling or degradation in lyso-
somes. Pinocytosis, together with exocytosis, therefore
contributes to the cellular membrane balance. Due to
their small size, solid NPs can be internalized via these
non-phagocytic pathways. Unlike phagocytosis, which is
restricted to specialized cells, these endocytic pathways
can be conducted by almost every cell type, including
neurons.
Types of Pinocytosis
There are two major types of pinocytosis: fluid-phase
endocytosis and receptor-mediated endocytosis.
Fluid-phase Endocytosis. Fluid-phase endocytosis (FPE) is a
non-specific mechanism used for the uptake of com-
pounds contained in the extracellular fluid. The main
characteristic of this process is its lack of selectivity. It
results in the uptake of the extracellular fluid surround-
ing the cell by means of an invagination of the plasma
membrane to form an endocytic vesicle. The attachment
of molecules to the cell surface takes place by means of
non-specific mechanisms such as electrostatic interac-
tions, hydrogen bonding or van der Waals forces,
amongst others (9). Cationic molecules interact with the
negatively charged plasmatic membrane, thereby facilitat-
ing their internalization. This has led to the proposal that
cationization might be a strategy to enhance drug delivery
to the CNS (10). Indeed, the most successful strategies for
delivering genetic material to the CNS have involved the
use of positively charged NPs.
Receptor-Mediated Endocytosis. This process is fully specific
and takes advantage of the high affinity binding constants
between the receptors and their specific ligands. Two
different mechanisms have been defined, namely constitu-
tive (class I) receptor-mediated endocytosis (RME), which
involves internalization of the ligand bound to its receptor
without the generation of any signal, and ligand-stimulated
(class II) RME, which involves internalization of the ligand-
receptor complex following the generation of signalling
molecules. CNS cells are highly differentiated from other
body cells. This differentiation also results in the existence
of CNS-specific receptors. Neurons express a number of
different classes of receptors, including neuropeptide,
neurotrophin and neurotoxin receptors (4), thereby leading
to strategies that are focused on brain drug-delivery that
take advantage of the high specificity of ligand-receptor
binding. The transferrin (Tf) or low-density lipoprotein
(LDL) receptors are among those defined as constitutive
(class I) receptor-mediated endocytosis, whereas others,
such as insulin or epidermal growth factor (EGF), are
referred to as ligand-stimulated (class II) receptor-mediated
endocytosis.
Molecular Mechanisms of Endocytosis
Clathrin-Mediated Endocytosis. Clathrin-mediated endocy-
tosis (CME) via clathrin-coated pits (CCPs) is the best
characterized pathway for cellular uptake (Fig. 1). The
CME pathway represents a common route of cellular
uptake for internalized ligands (11) and viruses (12), as well
as NP-based drugs or genetic material delivery systems (13).
NPs predominantly use this pathway for the intracellular
delivery of active molecules through receptor-mediated
endocytosis, such as those produced by Tf, low-density
LDL and EGF (14).
During CME, the membrane forms invaginations that
are coated by the protein clathrin. The GTPase dynamin,
along with other proteins, is mainly responsible for the
detachment of CCPs from the cell membrane.
CCPs also contain a high number of receptors that will
be involved in different interactions, such as lipid-lipid,
lipid-protein or protein-protein (15). These interactions
determine the vesicle function and target (16).
Receptor-mediated endocytosis provides the potential
for high selectivity in cellular targeting. The cellular
membrane expresses a limited number of specific
receptors, which can be used to bind NPs whose surface
is modified with receptor-specific ligands, thereby result-
ing in internalization of the ligand and its appended NP
via endocytosis.
CME, whether receptor-dependent or -independent, is
thus very important for drug-loaded nanocarriers, which
have to release their cargo intracellularly. CME is very
active in the nervous system, where it is responsible for
synaptic vesicle retrieval after nerve stimulation in the
retina (17), in either central nerve termini or neuromuscular
preparations following large non-physiological stimuli (18,
19) or after trains of action potentials within the physiolog-
ical range (20).
Caveolae-Mediated Endocytosis. Caveolae-mediated endo-
cytosis (CvME) also plays a role in cellular uptake of
different compounds (Fig. 1). Lipid rafts have been
defined as small (10–200 nm), heterogeneous, highly
dynamic, sterol- and sphingolipid-enriched membrane
domains that compartmentalise cellular processes (15,
21). The endocytic process that involves caveolae budding
is defined as a clathrin-independent pathway. Ligands
known to be internalized by CvME include folic acid,
albumin and cholesterol (15).
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The CvME pathway has received increasing attention
for drug-delivery applications using nanocarriers (12). Folic
acid, or vitamin B9, appears to be an attractive target for
NP-mediated drug or nucleic acid delivery using this
mechanism.
Designed nanocarriers exploiting CvME may be
employed to prevent degradation by lysosomal enzymes
when the cargo carried (e.g., peptides, proteins, nucleic
acids, etc.) is highly sensitive to lysosomal enzymes. In
addition, this mechanism might play an active role in
transcytosis (transport across a cell via endocytosis at one
side and exocytosis at the other) of specific membrane
proteins and ligands in endothelial cells (22) and therefore
might play a role in NP transcytosis and crossing of the
BBB (23).
Lipid rafts play important roles in neural tissue and
have been shown to be involved in growth factor
signaling by tyrosine kinase receptors (24), axonal
guidance (25), ionic channels traffic (26) and recycling of
receptors (27).
Non-clathrin, Non-caveolae-Mediated Endocytosis. Various
clathrin- and caveolae- independent endocytosis pathways
have been described and classified only recently (21)
(Fig. 1). However, the understanding of their involvement
in NP-mediated drug delivery is still at a nascent stage,
although it has been suggested than this mechanism is
present in the CNS (28).
Macropinocytosis. Macropinocytosis is another type of
non-clathrin, non-caveolae endocytic pathway (29) that
can occur in all cell types at different rates (30) (Fig. 1).
Macropinocytosis refers to the generation of large endo-
cytic vesicles (up to 5 μm in diameter), which is associated
with the formation of actin-dependent membrane ruffles
(29). This uptake mechanism shows poor selectivity and is
involved in the uptake of NPs (31). In some cases, the size
of the NPs has a much lower influence on uptake than
their surface properties (e.g., charge and presence of
ligands). Macropinocytosis is an attractive pathway to
explain the uptake of large NPs in both glial and neural
cells.
Non-endocytotic Pathway/Transduction. A non-endocytotic
pathway, called transduction, for the taking-up of NPs
occurs in many cell types and even in artificial unilamellar
vesicles (32) (Fig. 1). However, few efforts have aimed to
study this mechanism. There are two models proposed to
explain it: the “direct membrane penetration” model and
the “inverted micelle” model (32, 33), both of which
propose a three-step internalization process involving
membrane interaction, membrane permeation and release
of NPs into the cytosol.
LYSOSOMES, A CRITICAL BARRIER
FOR NANOCARRIERS
Lysosomes are probably the most important barrier to
genetic material delivery to different cell types, including
neurons. Following endocytosis, the vacuoles become
accessible to early endosomes, before fusing with late
endosomes and, finally, with lysosomes to form a phag-
olysosome (34). The lysosomal environment, which is
characterized by a low pH and the presence of hydrolytic
enzymes, can rapidly degrade a broad range of NPs and
their attached cargos, including DNA, RNA, many proteins
and therapeutic agents. It is, therefore, not surprising that
endosomal escape has been identified as a major limiting
step for the effectiveness of NPs in the CNS (35).
Differences in intracellular trafficking can occur mainly
based on different uptake mechanisms, so the clathrin-
dependent RME pathway is linked to lysosomal degrada-
tion, while the clathrin-independent RME internalization
favours endosomal accumulation and sorting to a non-
degradative pathway (36). NPs internalized by endocytosis
are therefore enclosed in vesicles from which they must
escape to find the target sites of their cargos before they
enter the degradation pathway of the lysosome.
Different endosome escape mechanisms, such as a
possible swelling of the NPs resulting from an increased
repulsion between the protonated groups, have been
suggested (37). Indeed, NPs resulting from the complexa-
tion with poly(ethyleneimine) (PEI) showed remarkable
transfection efficiency in various cell lines, leading to the
proposal of the so-called “proton-sponge” effect (38).
According to this hypothesis, the decrease in endosomal
pH results in a high protonation of PEI and therefore an
osmotic swelling and subsequent vacuole disruption, releas-
ing the NPs and their cargo (38). Although the precise
mechanism of the endo/lysosomal escape is not yet clearly
understood, PEI-based NPs have been found to perform
better than other types of NPs. Indeed, they remain one of
the best transfection agents due to the ability to escape from
the endosomes. In addition to PEI, other ligands such as
DOPE (dioleoylphosphatidylethanolamine) molecules and
some thiol groups have been shown to promote leakage
from the endosomes (39). Moreover, other strategies to
improve lysosomal escape have been used. Thus, NPs
linking together two different kinds of RNA, namely pRNA
(packaging RNA), which acts as the delivery vehicle, and
siRNA, which acts as the therapeutic agent, have been
generated (40). Finally, a recent study has described a
promising multifunctional nanosystem known as “super
pH-sensitive multifunctional polymeric micelles” (41).
Some additives can promote lysosomal escape in
neuronal cells. Thus, when SH-SY5Y and N18-RE105
neuronal hybrid cells were transfected in the presence and
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absence of chloroquine, transfection efficiencies in the
presence of chloroquine were enhanced 600- and 250-
fold, respectively (42). Furthermore, some studies have
determined that positive charges on the surface of NPs are
important to stimulate efficient uptake and endosomal
escape, and that other surface modifications such as
arginine are also important for an efficient escape (43).
NUCLEAR DELIVERY OF NANOCARRIER CARGOS
The nuclear targeting of NPs is an active area of research in
the field of gene delivery. Although it has been reported
that some naked DNAs can diffuse from the cytosol to the
nucleus across the nuclear membrane, it is hard for large
DNA molecules to cross the nuclear membrane while
cytoplasmatic nucleases are contributing to DNA degrada-
tion, thereby reducing transfection efficiency (44). More-
over, it has been reported that less than 1% of plasmid
DNA (pDNA) introduced into the cytoplasm eventually
reaches the nucleus, thus resulting in poor gene expression
(45), whereas the injection of pDNA directly into the
nucleus results in high gene expression.
The nucleus is surrounded by a double membrane which
contains highly regulated transport structures called nuclear
pores (NPC). There seem to be three possible routes for
DNA entry into the nucleus: i) entry during mitosis when
the nuclear envelope breaks down, ii) transport through
nuclear pores, and iii) active transport across the nuclear
membrane by using kariophilic proteins as transfer carriers
(Fig. 2).
Nucleocytoplasmic trafficking allows the free diffusion of
cargo molecules (plasmid DNA or gene-regulating proteins,
oligonucleotides and peptides) up to 9 nm in diameter
(about 50 kDa). On the other hand, active transport
requires the presence of a nuclear localization signal
(NLS) in the cargo that binds to nuclear import machinery
and subsequently translocates across the NPC (46).
In constantly dividing cells, the nuclear membrane
breaks down at the end of each mitosis, thus allowing the
passive inclusion of transfected DNA. However, in non-
dividing cells, including post-mitotic neuronal cells, in
which mitotic activity is absent, low pDNA nuclear
translocation occurs, probably as a result of passive
movement through the NPC or by fusion of lipoplexes
with the nuclear membrane (47) (this amount being
negligible). The primary barrier to DNA transfection in
post-mitotic cells is thus assumed to be DNA translocation
to the nucleus (48), and several strategies have been
described to improve nuclear delivery. Different NPs
therefore have different abilities to deliver their cargo to
the nucleus.
Cationic Lipids
Cationic lipids, which are commonly comprised of a polar
headgroup and non-polar symmetric or dissymmetric
carbon-based tail, condense and protect nucleic acids from
degradation in the extracellular environment (49) (Fig. 3).
Once lipoplexes escape from the endosome, the pDNA
appears to dissociate from the cationic lipid and moves
uncoated through the cell into the nucleus. Several studies
have shown that high levels of reporter gene expression by
lipofection are only obtained in actively dividing cells
progressing through the cell-cycle M phase (50).
It has also been postulated that pDNA nuclear entry
could also occur by passive diffusion or energy-dependent
passage through the NPC (51). Transfection of NIHT3 with
Fig. 2 Scheme showing the
mechanisms of nanoparticle (NP)
crossing through the nuclear pore
complex (NPC) to deliver its
attached cargo.
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Lipofectamine Plus resulted in the presence of rhodamine-
labeled DNAs in the nucleus of the cells within 0.5 to 1 h of
incubation, thereby indicating that DNA can enter the nucleus
in the presence of the nuclear membrane (52). The fact that
only naked DNA was visualized in the nucleus indicated that
the lipoplex-containing DNA fused with the nuclear mem-
brane and released naked DNA into the nucleus (52). The
driving force proposed for the lipoplex to gain access to the
nucleus from cytoplasm involves electrostatic interactions
between the positively charged lipoplex and the negatively
charged lipids in the nuclear membrane. Lipoplex fusion with
the nuclear membrane might therefore be interrupted by
non-specific binding with other membranes of intracellular
organelles, such as mitochondria, thus resulting in low levels
of aggregates reaching the nucleus.
The fusion hypothesis was also supported by reports
showing that lipofection allowed transgene expression in
neuronal cells (3). This hypothesis would also explain the
low levels of transfection efficiency reported for delivery of
pDNA to neuronal cultures, with only Lipofectamine 2000
reaching a transfection efficiency of about 25% in primary
cortical and hippocampal neurons (3, 53).
One of the main strategies used to improve pDNA
import into the nucleus, especially in non-dividing cells,
involves the non-covalent and covalent attachment of NLS
peptides or nuclear proteins to the pDNA itself or a cationic
counterpart (54). The need for nuclear targeting agents in
lipoplex vector design was initially described by Holmes
and co-workers after examining the DNA distribution in
human airway epithelial cells after lipoplex delivery (55).
However, it should be noted that although nuclear targeted
proteins facilitate nuclear transport of pDNA, it is unclear
how efficiently these proteins release DNA once the
complex arrives to the nucleus. In agreement with this, it
has also been reported that NLS peptides could result in a
loss of biological activity of pDNA (56).
PEI Derivatives (Cationic Polymers)
Polyethyleneimine is an organic molecule with a high
cationic-charge-density potential based on the presence of
multiple amino groups within its backbone (Fig. 3). In
addition, PEI is able to retain an important buffering
capacity at virtually any cellular pH, thus protecting pDNA
and avoiding lysosomal nuclease degradation.
Once PEI polyplexes escape from the endosome, they
enter the nucleus by a mechanism which is still unclear.
Some studies have suggested that nuclear entry of the DNA
complexed with branched or linear PEI does not require
cell division (50), whereas others appear to show a cell-
cycle-dependent transfection efficiency for branched PEI/
DNA polyplexes (57).
A mitosis-dependent mechanism would be consistent
with the low transfection efficiency obtained in postnatal
primary neurons, including primary cultures of granular
cells of the cerebellum, hippocampal pyramidal neurons,
primary sensory neurons of the dorsal root ganglia and
sympathetic neurons from the superior cervical ganglia (58).
Initial experiments in this area showed that the transfection
efficiency was about 1% for cerebellar granule cells and
about 20% for sympathetic neurons from the superior
cervical ganglia. However, although a mitosis-dependent
mechanism has been postulated for branched PEIs, better
transfection efficiencies in rat cerebral glial cells and rat
cortical neurons have been achieved using low-molecular-
weight branched PEI derivatives (59), thus indicating that
Fig. 3 Structure of different nano-
particles. Linear polyethyleneimine,
branched polyethyleneimine,
cationic lipids where the green ball
represents the cationic polar head
group, while the red tails symbol-
izes the hydrophobic carbon
skeleton, dendrimer and a single-
walled carbon nanotube where
the blue and red balls represent
different functionalizations.
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even if the main mechanism of nuclear delivery is mitosis-
dependent, other mechanisms, probably passing through
the NPC or neuronal uptake mechanisms, also contribute
to polyplex translocation into the nucleus.
Once in the nucleus, cationic polymers appear to
dissociate from pDNA by exchange of the polymer with
the components of the surrounding chromatin. Thus,
dissociation of the PEI-DNA complexes seems to be the
most important factor for transgene expression (60). A
recent study has shown that a greater number of pDNAs
are delivered into the nucleus by PEI than by Lipofect-
amine. However, although fewer pDNAs reached the
nucleus after transfection with Lipofectamine, a higher
percentage of the cells transfected with Lipofectamine
expressed the reporter gene (61). This is probably due to
differences in the transcriptional activity of pDNAs trans-
fected into cells using either cationic lipids or cationic
polymers. Dissociation of pDNA from cationic polymers in
the nucleus may interfere with transcription until the
polymer completely dissociates from DNA. Moreover, it
has been described recently that cationic polymers con-
dense pDNA more efficiently than cationic lipids and that
pDNA decondensation in the nucleus, which is required in
order to use the innate transcription machinery and to
express the encoded protein, appears to be the major
limiting step for transgene expression (60).
Since it has been established that cell division is not
absolutely required for nuclear entry by polyfection, several
strategies have been developed to overcome the nuclear
barrier, including NLS, glycosyl residues or glucocorticoid
ligands. Recently, it has been described that coupling a classical
(SV40) or non-classical (TAT) NLS peptide to PEG-DNA
binding peptides-PEI increased transfection efficiency (62).
The use of glucocorticoid receptor (GR) ligands as an
NLS to enhance transgenic expression is an alternative
strategy. Glucocorticoid receptor is a nuclear receptor
which is mainly located in the cytoplasm. Upon binding
to the ligand, GR translocates from the cytoplasm into the
nucleus, dilating the nuclear pore by up to 60 nm and
facilitating the transport of associated molecules. The
combination of different glucocorticoids with branched
PEI has been found to efficiently condense pDNA into
small NPs with sizes of around 100 nm. The transfection
efficiency increased in the same order as the potency of the
glucocorticoid irrespective of the cell type (63). Moreover,
triamcinolone acetonide (TA), a potent glucocorticoid,
translocates PEI 600-TA and PEI 1800-TA into the
nucleus more efficiently than PEI 25 k-TA (64).
Dendrimers
Dendrimers are highly ordered and well-defined macro-
molecules that will be described in more detail below
(Fig. 3). Biologically, these molecules could efficiently
induce expression of a reported gene in a variety of
suspension- and adherent-cultured mammalian cells. Den-
drimers are the non-viral vectors which display the highest
transfection efficiency in neuronal cells, with arginine-
grafted G4-PAMAM dendrimer, for example, achieving a
transfection efficiency of 35%–40% in primary cortical
neurons (65). Likewise, PAMAM esters allow siRNA
delivery to a primary culture of mixed cortical cells
containing neurons and glia, achieving an 80% reduction
in the target protein (66), and the ammonium-terminated
carbosilane dendrimer NN16 has been used to efficiently
transfect siRNA in a primary culture of rat cortical
neurons, with a resulting reduction in the total protein
content of about 80% (67).
Different dendrimer modifications have been performed
to improve pDNA transfection efficiency. Thus, the
combination of G4-PAMAM dendrimer with glucocorti-
coid dexamethasone (PAM-Dex) facilitates polymer/pDNA
complex nuclear translocation and increases pDNA trans-
fection delivery in Neuro2A cells more than two-fold with
respect to PEI and more than six-fold with respect to
PAMAM alone (68). Similarly, the combination of the
highly potent glucocorticoid TA with PAMAM G4 den-
drimer resulted in a transfection efficiency more than four
times higher than native PAMAM. These results support
the hypothesis that TA residues act as an NLS, thereby
facilitating PAMAM polymer/pDNA entry into the nucleus
and enhancing transgene expression (63).
Although numerous efforts have been focused on
increasing nuclear pDNA delivery to enhance transgene
expression by modifying the different non-viral vectors
available, it should be noted that, in contrast to pDNA
delivery, the use of small interference RNA (siRNA) avoids
the need for nuclear translocation and greatly improves
transfection of post-mitotic cells (69). In this regard, Zou
and co-workers have recently described that siRNA is
between two and five times more efficient than DNA in
transfecting cells in a primary mixed neuronal culture (70).
CROSSING THE BLOOD-BRAIN BARRIER
The following section will focus on a brief description of the
BBB and the characteristics common to those species that
are able to cross it. Recent reviews have covered this subject
in greater detail (71).
The BBB is a physical barrier which limits the brain
uptake of the vast majority of neurotherapeutic and
neuroimaging contrast agents. This barrier normally has
to be overcome to reach brain tissue, although an
alternative pathway using the naturally occurring trans-
synaptic retrograde transport route of entry into the CNS
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from the peripheral nerves could be another possible route
for CNS entry. Nanotechnology may provide an effective
means of delivering therapeutic agents into the CNS
following peripheral administration, although NPs must
either first overcome the BBB or circumvent it by traveling
through peripheral nerves.
The BBB is composed of a dense layer of capillary
endothelial cells facing the bloodstream which separates the
CNS (i.e. brain and spinal cord) from the rest of the
organism by means of tight junctions (zonulae occludens). On
the brain side, this layer of non-fenestrated endothelial cells
is lined by astrocytes, pericytes and neurons. Paracellular
transport in brain capillary endothelial cells is restricted by
expression of tight junctional proteins that afford high
resistance to the cell, and this is associated with limited
endocytosis across the endothelium (72). The blood-brain
barrier is known for its high selectivity as well as its high
transendothelial electrical resistance, with reported values
ranging from 1500 to 8000Ω cm2 (depending on the
authors) (73). This value is about three orders of magnitude
higher than that present in other tissues (3–33Ω cm2), thus
resulting in a reduction of the aqueous paracellular
diffusion. Indeed, only small hydrophilic compounds with
a mass lower than 150 Da and highly hydrophobic
compounds with a mass lower than 400–600 Da can cross
the membrane by passive diffusion.
Characteristic features of BBB microvessels include their
smaller diameter and the fact that their walls are thinner than
those of other vessels in the organism. These vessels are highly
dense in mitochondria, mainly due to the lack of cytoplasm
surface in their endothelial cells. As a result of this high
mitochondrial area, those drugs that cross the BBB are very
likely to be degraded enzymatically. In terms of selectivity, the
efficient efflux pump system composed of p-glycoprotein
located in the cerebral capillary endothelium should also be
mentioned. This pump is involved in recognition of those
molecules necessary for the brain and the prevention of other
molecules from entering the brain parenchyma (74). More-
over, transcytosis, the process used by nanocarriers to pass
across the BBB, is partly prevented by the activity of efflux
pumps like p-glycoprotein. NPs should therefore gain access
to the CNS by lipid-mediated free diffusion or potentially by
receptor-mediated endocytosis.
The distinctive chemical nature of those drug molecules
that have been proved effective in the CNS (e.g. hydro-
phobic benzodiazepines and the highly polar L-DOPA)
makes it difficult to achieve a comprehensive understanding
of the mechanisms that regulate their passage across the
BBB. Moreover, based on the transport of some hydrophil-
ic drugs, several NPs can transiently and reversibly open the
tight junctions located at the BBB and other sites, thus
increasing their paracellular permeability (75). Neverthe-
less, it is known that tight junctions can be opened up to
20 nm wide (76); thus, only NPs smaller than this can use
this pathway to penetrate into the brain through the BBB.
Trans-synaptic retrograde transport could enable some
types of nanocarriers with a specific size and surface
modifications to travel from peripheral nerve terminals to
neuronal cell bodies in the CNS (as occurs with the
transport of some pathogens and toxins), where they can
deliver therapeutic agents (77). Studies in this regard have
shown that NPs modified with PEI and other polyplexes
display active retrograde transport along neurites but are
unable to mediate efficient biological actions upon reaching
the neuronal body (78). In contrast, other studies have
shown that some NPs cannot travel through peripheral
nerves, although they produce efficient neuronal transfec-
tion if they are delivered directly to neuronal cell bodies
(78). It has been proposed that the differences in uptake
pathways and efficiencies between neuronal soma and
neurites are related to either the differing surface properties
of both cellular areas (79), the lower efficiency and higher
selectivity shown by neuronal processes for internalizing
small size particles (80), or the inability of neuronal
processes to internalize and transport relatively large NPs
to cell bodies.
Transcellular transport may be mediated by transferrin
(Tf) receptors, which are highly expressed in some healthy
tissues such as brain capillaries. Interestingly, several in vitro
and in vivo studies have shown that NPs conjugated with Tf
penetrate the BBB much more easily, thereby significantly
improving the delivery of active molecules to rat brain with
respect to the same NPs devoid of the ligand (81).
Other strategies to increase passage through the BBB
have been studied. Thus, nanoparticles conjugated with
PEG or monoclonal antibodies have been shown to
translocate into brain tissue after intravenous administra-
tion, thus suggesting a critical role for these proteins in NP
endocytosis by the brain endothelial cells (82). Surface
modifications of NPs in order to improve their passage
across the BBB can, however, decrease their ability to
breach other barriers; therefore, the delivery of active
molecules by NPs into cells of the CNS remains a
challenge.
NANOPARTICLES AND THEIR ROLE IN GENE
DELIVERY TO THE NERVOUS SYSTEM
Nanomaterials have at least one of their dimensions within
the nanometer (10−9 m) range and exhibit electromagnetic,
photophysical and/or structural properties that are directly
related to their nanometric size. Indeed, the size of these
materials has been shown to result in interesting biological
properties, some of which have been successfully applied to
gene-delivery processes.
1850 Pérez-Martínez, Guerra, Posadas and Ceña
The efficiency of the uptake process using non-viral
gene-delivery agents depends on the cell type, the target site
and the specific carrier composition. In the case of neurons,
this is very important since neurons are highly polarized
cells whose somal, axonal and dendritic domains have
distinct membrane compositions (80).
In this section, we will study the effectiveness of the
aforementioned nanoparticles to deliver genetic material
(DNA, mRNA or siRNA) to the cytoplasm of CNS cells,
taking into account that neurons are a difficult cell type to
transfect both in vitro and in vivo.
Cationic Lipids and Cationic Liposomes
Efforts to find efficient vectors for gene therapy have also
focused on small molecules, such as liposomes, which have
been found to enter cells through RME via the CCP
pathway as well as by direct fusion with the membrane (83,
84). Since the synthesis of DOTMA (N-2,3-dioleoyloxy-
propyl)-N,N,N-trimethylammonium chloride) by Fegner
and co-workers (85), which was subsequently commercial-
ized as part of Lipofectin®, cationic lipids have been widely
used in gene transfer (86). Their structure involves a
cationic head group, a linker and a hydrophobic part.
The positive charge allows interaction with the genetic
material by means of electrostatic interactions. Cationic
lipids generate liposomes, which are hollow spheres with an
aqueous core with a diameter of 100 to 400 nm (85). The
surface of the liposome is positively charged and can
therefore interact with the negatively charged cell mem-
brane. This results in the DNA becoming coated and the
formation of a lipocomplex, which is subsequently incor-
porated into the cell by endocytosis (87).
In terms of cell differentiation in the CNS, it has also
been shown that the binding and internalization of cationic
lipid-based gene carriers is more efficient at neuronal soma
than at neurites (78). Lipofectin® is a very poor transfectant
(0.02%–0.5%) in primary septo-hippocampal neuronal
cultures (88), although its transfection efficiency increases
to about 25% in primary E18 rat cortical neurons and E18
rat hippocampal neurons (2, 87).
One strategy for increasing the transfection efficiency of
cationic lipids involves adding molecules that can facilitate
either uptake or endosomal escape. The incorporation of
targeting ligands such as Tf or antibodies within these
lipoplexes has resulted in efficient nucleic acid delivery to
neurons in the CNS by means of systemic administration
(89). Transferrin receptor is a ubiquitous membrane
receptor that can mediate endocytosis, and several cationic
lipoplexes associated with Tf have been shown to provide
good results in the delivery of anti-c-Jun siRNAs to
neuronal cells in culture. This process resulted in the
efficient silencing of c-Jun mRNA and protein and a
significant decrease of cell death following glutamate-
induced damage or oxygen-glucose deprivation. Tf-
lipoplexes have also led to a significant c-Jun knockdown in
the mouse hippocampus in vivo, and it has also been shown
that Tf-lipoplexes promote siRNA delivery and siRNA-
mediated protein silencing in the brain with high efficiency
and minimum toxicity following stereotactic injection (90).
Although an overall positive charge in the lipoplex
favours binding to the cell membrane, such binding has
also been reported with neutral immunoliposomes (91).
PEGylation not only prevents complex aggregation but also
several undesirable effects reported for non-PEGylated
complexes, including erythrocyte aggregation and binding
of complexes to plasma proteins such IgM, fibronectin and
complement C3 (92).
Polyethyleneimine Derivatives
As mentioned above, polyethyleneimine (PEI) is an organic
molecule produced by the polymerization of aziridine in
which every third atom is an amino nitrogen that can be
protonated and can bind nucleic acids (Fig. 3). PEI will
spontaneously adhere to and condense DNA to form
toroidal complexes that are readily endocytosed by cells.
Furthermore, it has been shown that PEI complexes are
introduced into the cell by adsorptive endocytosis, with no
inhibition of the endocytic uptake of a non-digestible fluid-
phase substrate such as fluorescein isothiocyanate (FITC)-
dextran. However, it has also been reported that PEI/DNA
complexes are effectively endocytosed, probably as a result
of interaction with cell-surface molecules such as proteo-
glycans, more specifically syndecans (93).
Linear or branched polyethyleneimines (lPEI and bPEI,
respectively) have been considered to be promising cationic
polymers that can act as non-viral vectors for DNA or siRNA
delivery since the last decade and are currently considered to
be gold standards when studying the gene-transfer efficiency
of a new vector. bPEI usually gives better transfection results
than lPEI, probably as a result of the size of the final polyplex,
as lPEI forms larger particles that could be more difficult to
endocytose. Thus, a transfection efficiency of about 9% in
primary sympathetic neurons was obtained using 22 K lPEI
(94), whereas bPEI (600–800 kDa) gave a transfection
efficiency of 15% in rat hypothalamic neurons (2). When
compounds with a similar molecular weight are compared,
25 kDa bPEI provides higher transfection efficiencies than
25 kDa lPEI in rat cerebral glial cells and rat cortical
neurons. As mentioned previously, bPEI generates smaller
complexes with the genetic material (59), thereby facilitating
uptake by clathrin-mediated endocytosis, where the typical
size limitation is about 200 nm. Particle charge may also
influence the uptake mechanism and efficiency in the gene
delivery (78).
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Receptor-mediated endocytosis is the most selective
strategy to reach CNS cells. Thus, conjugation of hydro-
phobic molecules, such as cholesterol, to PEI enables the
formation of WSLP (water-soluble lipopolymers), which go
on to form micelles in aqueous solution. This micelle
formation could condense the WSLP/DNA complex and
facilitate its interaction with, and uptake into, target cells.
The presence of cholesterol in these micelles could allow
the lipoplex to incorporate into LDL and enter cells by
LDL receptor-mediated endocytosis (95, 96).
TrkA or the p75NTR receptors for neuronal growth
factors (NGF) have been targeted as entrance portals for
PEI polymer-based polyplexes. Thus, Zeng and co-workers
added the nerve growth factor loop 4 hairpin structure to
the polyplex (97) to form complexes which target cultured
cells expressing the TrkA receptor. The same authors also
used these vector-driven polyplexes in dorsal root ganglia,
which resulted in a decrease in the toxicity caused by non-
specific uptake of large amounts of higher-molecular-weight
PEI. Transferrin has also been successfully added to
PEGylated PEI/DNA polyplexes (98).
Neurotoxin receptors are also important receptors to be
studied for access to CNS cells. Tetanus toxin (TeNt), for
instance, is a good ligand to imitate, with TTC, the
purified, recombinant heavy chain fragment of TeNT,
being responsible for TeNT cell binding and retrograde
axonal transport (4). Liu and co-workers have identified a
12-amino acid peptide, Tet1, which mimics the receptor-
binding properties of TTC (99). Conjugation of Tet1 to
PEI resulted in specific uptake of Tet1-modified PEI/DNA
polyplexes by cells expressing TTC receptors (100).
Dendrimers
Dendrimers are attractive molecules which are related to
hyperbranched polymers but with a well-defined structure
and a polydispersity close to 1.0. These macromolecules are
globular and nanoscaled and have a unique architecture
containing three distinct domains: a central core (either a
single atom or a group having at least two identical
chemical functionalities); branches emanating from the
core, which are composed of repeat units with at least one
branching junction whose repetition is organized in a
geometric progression that results in a series of radially
concentric layers named generations (G); and terminal
functional groups, which are located on the exterior of the
macromolecule and facilitate interactions with solvents,
surfaces or other molecules (Fig. 3).
Poly(amidoamine) (PAMAM) dendrimers, also known as
Starbust dendrimers, were synthesized by Tomalia and co-
workers in 1985 and are probably the most widely studied
(101). The transport of PAMAM dendrimers and their
derivatives across the cell membrane follows an endocytic
pathway (102). Several factors, including the dendrimer’s
molecular mass, the functional groups on its periphery (103)
and cholesterol levels, are known to modulate this trans-
port, thus suggesting that membrane cholesterol and raft
integrity are physiologically relevant for the cellular uptake
of dendriplexes (104). Dendrimers have been shown to cross
cell barriers at sufficient rates to act as potential carrier/
delivery systems (105).
It has also been shown that dendrimer nanocarriers can
be used to enhance the transport of propranolol across the
membrane of Caco-2 cells. Propranolol is an insoluble drug
and a substrate for the p-glycoprotein efflux transporter.
When conjugated to G3 PAMAM, propranolol was shown
to bypass the efflux system. Dendrimer nanocarriers may
therefore also be used to enhance the bioavailability of
drugs that are poorly soluble and/or substrates of efflux
transporters (102).
Transmission electron microscopic analyses of cells
incubated with gold-labelled G3 PAMAM dendrimers
confirmed endocytosis-mediated cellular internalisation
when these dendrimers were applied to the apical domain
of Caco-2 cells. These findings are in agreement with
similar previous studies using Caco-2 cell monolayers,
which showed a significant decrease of dendrimer uptake
in the presence of colchicine (endocytosis inhibitor) and
when the temperature was lowered from 37 to 4°C (106).
These findings are consistent with transport involving both
trans- and paracellular pathways (107).
Enhancement of gene transfer has also been observed
when PAMAM structures are modified with less polar
moieties such as PEG groups. When PEG is located on the
periphery of the dendrimer, non-specific adsorption to the
cell membrane and subsequent ingestion by endocytosis
rather than an electrostatic interaction can be observed in
cationic dendrimers (103). The combination of PEGylation
and addition of a ligand with affinity for the brain
(lactoferrin) also enhances the gene transfer efficiency.
The presence of lactoferrin favours endocytosis via a
receptor-mediated mechanism (108).
A more efficient way of increasing transfection efficiency
involves coupling either proteins or peptides to dendrimers.
Thus, when administered intravenously in the tail vein of mice,
transferrin-conjugated PEG-PAMAM and lactoferrin-
conjugated PEG-PAMAM efficiently deliver genetic material
to brain tissue, althoughmaximal gene expression was detected
in the kidney for both vehicles studied (108). Target protein
expression (GFP) was detected in cortex, hippocampus,
caudate putamen and substantia nigra, with lactoferrin-
conjugated PEG-PAMAM being more efficient for dendriplex
translocation into the brain across the BBB (108).
Angiopep-2 is one of the peptides derived from the
Kunitz domain that possesses a high brain penetration
capability (109). Thus, intravenous administration of
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surface-modified PEG-PAMAM with angiopep-2 into the
tail vein of mice has been found to result in a high
accumulation of target gene in brain and spleen (110).
Furthermore, in this case, internalization of the dendriplex
into brain capillary endothelial cells occurred mainly
through CvME and, partly, through macropinocytosis
(110). To increase NP entry into neurons, dendrimers were
covalently linked to rabies virus glycoprotein peptide
(RVG29) (111). Following intravenous injection, an accu-
mulation of the target gene in brain to a similar extent to
that observed in the spleen and heart could be observed.
Gene expression in the former was much higher in the
hippocampus and substantia nigra (112). The mechanism
involved in particle internalization seemed to be clathrin-
and caveolae-mediated energy-dependent endocytosis.
Arginine-modified PAMAM dendrimers show an en-
hanced gene-transfer activity in primary cortical neuronal
cultures (65), possibly due to the localization of the arginine
residues on the surface of PAMAM-Arg/DNA complexes,
which presumably facilitates uptake or nuclear localization
(113). Thus, an arginine-grafted G4-PAMAM dendrimer
has been reported to result in transfection levels of 35%–
40% in primary cortical neurons. These transfection levels
were significantly higher than those reported previously for
Lipofectamine®, 25-kDa bPEI and native PAMAM (65).
More recently, it has been reported that biodegradable
polycationic PAMAM esters in which arginine is bound to
PAMAM-OH functionalized dendrimers allow siRNA
delivery to a primary culture of mixed cortical cells
containing neurons and glia, thereby resulting in a
reduction of about 80% in protein levels 12 h post-
transfection, (114). Moreover, a second generation
ammonium-terminated carbosilane dendrimer containing
16 positive charges (NN16) has been shown to efficiently
transfect siRNA into rat cortical neurons. Thus, at 18 h
post-transfection, approximately 85% of neurons contained
fluorescein-labelled siRNA/2G-NN16 complex. Analysis of
the target protein (hypoxia-inducible factor (HIF)) showed a
reduction of about 80% of the total protein content with no
toxic effects on the neurons (67).
The cytotoxicity of cationic polymers has been reported
to be a function of the interaction between the polymer and
the cell membrane and/or of cellular uptake efficiency
(106, 113).
Carbon Nanotubes (CNTs)
These materials are a new allotropic form of carbon
which consist of seamless graphene sheets rolled concen-
trically to form capped cylinders mostly composed of
carbon hexagons and highly strained regions at the tips,
where carbon pentagons are the predominant shape.
Depending on the number of graphene layers, single-,
double- or multi-walled CNTs (SWNTs, DWNTs and
MWNTs, respectively) can be obtained. Thus, whereas
SWNTs are composed of a single monolayer of gra-
phene, MWNTs are composed of a concentric arrange-
ment of several nanotubes (Fig. 3). These nanomaterials
might play an important role in different fields, including
nanomedicine (115, 116).
The use of carbon-based nanomaterials has two main
disadvantages: lack of solubility and potential toxicity.
Pristine carbon nanomaterials have a poor solubility that
can be increased markedly by the incorporation of different
pendant units (116, 117). These structural modifications
can be performed in a non-covalent fashion by taking
advantage of electrostatic, π-π or van der Waals interac-
tions, amongst others, or in a covalent manner that results
in a chemical change in the surface structure. PAMAM
dendrimers have been anchored to the surface of carbon
nanotubes (118), and PAMAM dendron fragments attached
to the surface of carbon nanotubes have been shown to be
efficient for gene transfer (119). Experiments with mice
using CD80siRNA-SWNTs demonstrated an important
inhibition of CD80 expression in myeloid immunosuppres-
sive cells (120). Moreover, the injection of SOCS1siRNA-
SWNTs resulted in enhanced antigen-presenting function
of dendritic cells and therefore suppressed tumor growth
(120).
The second issue which must be resolved before CNTs
can be used in gene therapy is their possible toxicological
effects. CNTs are fiber shaped and therefore might
behave in a similar manner to asbestos and other
pathogenic fibers, which are toxic as a result of their
needle-like shape. On the other hand, CNTs are
essentially graphitic and are expected to be biologically
biopersistent in the organism, mainly in the lungs.
Moreover, it has been reported that intratracheal or
pharyngeal instillation of a SWCNT suspension in mice
resulted in a persistent accumulation of carbon nanotube
aggregates in the lung, followed by the rapid formation of
pulmonary granulomatous and fibrotic tissues at the site
(121), inflammatory reactions of the terminal and respira-
tory bronchioles, and, in some animals, mild fibrosis in the
alveolar septa (122).
Various studies have suggested endocytosis as the
cellular uptake mechanism for CNTs (123), although
phagocytosis and diffusion are also claimed to be possible
mechanisms. In a recent review, it has been concluded that
phagocytosis appears to be the internalization pathway for
CNT aggregates (124), bundles, clusters or singly dispersed
CNTs 1 μm or more in length, while endocytosis is the
internalization mechanism for CNTs forming supramolec-
ular structures, and diffusion is the internalization mecha-
nism for submicron CNTs that do not form supramolecular
complexes. In any case, the aggregation or individualization
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of carbon nanomaterials can determine the entry mecha-
nism into the cell as well as the excretion pathway. For
instance, individualization of these materials seems to lead
to an excretion pathway through the kidney (118).
However, the most widespread point of view is that the
uptake of CNTs by cells involves clathrin-dependent
endocytosis (123). Endocytosis is an energy-dependent
mechanism which is characterized by its temperature
dependence (125). Although the majority of published
studies agree on an endocytosis-based model (124),
energy-independent cell uptake with CNTs has also been
reported (126). Indeed, a quantitative kinetic model to
correlate endocytosis rate with NP geometry, which
accurately describes experimental data sets studying the
cellular uptake of SWNTs in NIH-3T3 cells by measuring
the SWNTs’ intrinsic photoluminescence, has been pub-
lished recently (127). This model has been validated for
DNA-wrapped single-walled carbon nanotubes with lengths
ranging from 130±18 to 660±40 nm. The maximum rate
observed for CNTs occurs at a length of 320 nm, with
longer CNTs showing a lower entry rate.
As an alternative explanation, it has been proposed that
both negatively and positively charged single MWCNTs
enter human embryonic kidney epithelial cells (HEK293)
by direct penetration, whereas MWCNT bundles enter by
endocytosis (128).
FUTURE DIRECTIONS
The routine administration of genetic material to neurons
for therapeutic purposes will inevitably involve nanomedi-
cine and, more specifically, therapeutic nanoparticles due
to the numerous problems posed by viral vectors. However,
the development of therapeutic nanoparticles for treating
CNS diseases needs to overcome mainly two types of
problems before it can be used as a routine therapy:
biocompatibility/biodistribution and targeted delivery.
Biocompability and Biodistribution
The most relevant problem is to design nanoparticles able
to efficiently cross the BBB. This is perhaps the most
important brake to the development of nanoparticles. At
the present moment, the most relevant advances came
from the use of molecules, like transferrin, which facilitate
BBB crossing. During the next few years, we are likely to
see the progressive development of new chemical for-
mulations to overcome the BBB problem, thereby allow-
ing a more efficient delivery of nanoparticles to brain
tissue. One possible line of research might come from the
use of NPs coupled to inhibitors of the efflux pumps.
However, a better understanding of the mechanisms
involved in NPs crossing the BBB is required for proper
design of more effective NPs.
Target-Directed Nanoparticles
The specific delivery of therapeutic nanoparticles is probably
the most challenging task which lies ahead in the field of
nanoparticle therapeutics. Nanoparticles can be directed to
either specific cell types or intracellular organelles.
For cell-type-specific targeting, future developments
probably will rely on the use of specific drugs with affinity
for different types of receptors that would take advantage of
the receptor-mediated endocytotic pathway. An alternative
approach might be the development of antibodies against
specific membrane proteins in the different types of
neurons. Advances in this field are especially relevant for
the CNS, where there is little information on what proteins
are specific and unique to the different types of neurons and
glial cells involved in the genesis of different diseases, thus
making it difficult to selectively direct a therapeutic nano-
particle to a given neuronal type. If this problem can be
solved, the possibilities of gene therapy in the nervous
system will be markedly improved.
The second target-directed approach is to deliver specif-
ically the nanoparticles to different intracellular organelles.
For this, it is expected that the coupling of signalling peptides
to the different nanoparticles can direct the nanoparticles to
the different subcellular organelles. Since different organelle-
specific sequences are already known, a rapid pace progress
in this field would be expected.
We are now at the beginning of a new area of nervous
system therapeutics based on the use of nanoparticles as
carriers to deliver genetic material, peptides and drugs to
the nervous system. Whether this new area will progress at
a fast pace will depend mainly on the solutions that
research will provide to the problems raised above.
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